Chapter title |
Circulating Tumor Cells
|
---|---|
Chapter number | 10 |
Book title |
Novel Biomarkers in the Continuum of Breast Cancer
|
Published in |
Advances in experimental medicine and biology, January 2016
|
DOI | 10.1007/978-3-319-22909-6_10 |
Pubmed ID | |
Book ISBNs |
978-3-31-922908-9, 978-3-31-922909-6
|
Authors |
Costanza Paoletti, Daniel F. Hayes |
Abstract |
Circulating Tumor Cells (CTC) are shed from primary or secondary tumors. Prior studies have demonstrated that enumeration of CTC is a robust independent prognostic factor of progression free and overall survival in patients with early and metastatic breast cancer. CTC, as well as other circulating tumor markers, have the appealing advantages over tissue biopsy of (1) ease of collection, (2) serial evaluation, and (3) interrogation of the entire tumor burden instead of just a limited part of the tumor. Advances have been recently made in phenotyping and genotyping of CTC, which should provide insights into the predictive role of CTC for sensitivity or resistance to therapies. In addition, CTC phenotypic marker changes during the course of treatment may serve as pharmacodynamic monitoring tools. Therefore, CTC may be considered "liquid biopsies," providing prognostic and predictive clinical information as well as additional understanding of tumor heterogeneity. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
India | 1 | <1% |
United States | 1 | <1% |
Unknown | 128 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 20 | 15% |
Researcher | 20 | 15% |
Student > Bachelor | 14 | 11% |
Student > Master | 11 | 8% |
Student > Doctoral Student | 8 | 6% |
Other | 21 | 16% |
Unknown | 37 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 27 | 21% |
Medicine and Dentistry | 19 | 15% |
Agricultural and Biological Sciences | 11 | 8% |
Engineering | 11 | 8% |
Chemistry | 7 | 5% |
Other | 17 | 13% |
Unknown | 39 | 30% |